Seminars in Nuclear Medicine
Volume 38, Issue 5 , Pages 308-320 , September 2008

State of the Art in Nuclear Medicine Dose Assessment

  • Michael G. Stabin, PhD, CHP

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Michael G. Stabin, PhD, CHP, Department of Radiology and Radiological Sciences, Vanderbilt University, 1161 21st Avenue South, Nashville, TN 37232-2675.
    • ,
  • A. Bertrand Brill, MD, PhD

References 

  1. Marinelli L, Quimby E, Hine G. Dosage determination with radioactive isotopes II, practical considerations in therapy and protection. Am J Roent Radium Ther. 1948;59:260–280
  2. Quimby E, Feitelberg S. Radioactive Isotopes in Medicine and Biology. Philadelphia: Lea and Febiger; 1963;
  3. Loevinger R, Budinger T, Watson E. MIRD Primer for Absorbed Dose Calculations. Reston, VA: Society of Nuclear Medicine; 1988;
  4. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310
  5. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection. (ICRP Publication 60). New York: Pergamon Press; 1991;
  6. Snyder W, Ford M, Warner G, et al. MIRD Pamphlet No 5 - Estimates of Absorbed Fractions for Monoenergetic Photon Sources Uniformly Distributed in Various Organs of a Heterogeneous Phantom. J Nucl Med Suppl. 1969;3:5
  7. International Commission on Radiological Protection. ICRP Publication 23, Task Group Report on Reference Man. Oxford: Pergamon Press; 1975;
  8. International Commission on Radiological Protection. ICRP Publication 89: Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values. New York: Elsevier Health; 2003;
  9. Snyder W, Ford M, Warner G. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. (MIRD Pamphlet No. 5, revised). New York: Society of Nuclear Medicine; 1978;
  10. Snyder W, Ford M, Warner G, et al. A Tabulation of Dose Equivalent Per Microcurie-Day for Source and Target Organs of an Adult for Various Radionuclides. (ORNL-5000). Oak Ridge, TN: Oak Ridge National Laboratory; 1975;
  11. Cristy M, Eckerman K. Specific Absorbed Fractions of Energy at Various Ages From Internal Photons Sources. (ORNL/TM-8381 V1-V7). Oak Ridge, TN: Oak Ridge National Laboratory; 1987;
  12. Stabin M. MIRDOSE: The personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538–546
  13. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–1027
  14. Stabin M, Watson E, Cristy M, et al. Mathematical models and specific absorbed fractions of photon energy in the nonpregnant adult female and at the end of each trimester of pregnancy. ORNL Report ORNL/TM-12907. 1995;
  15. Segars JP. Development and Application of the New Dynamic NURBS-based Cardiac-Torso (NCAT) Phantom, PhD Dissertation, The University of North Carolina. 2001;
  16. Spiers FW. Beta dosimetry in trabecular bone. In:  Mays CW editors. Delayed Effects of Bone-Seeking Radionuclides. Salt Lake City, UT: University of Utah Press; 1969;p. 95–108
  17. Eckerman K, Stabin M. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys. 2000;78:199–214
  18. Bouchet LG, Bolch WE, Howell RW, et al. S-Values for radionuclides localized within the skeleton. J Nucl Med. 2000;41:189–212
  19. Stabin MG, Eckerman KF, Bolch WE, et al. Evolution and status of bone and marrow dose models. Cancer Biother Radiopharm. 2002;17:427–434
  20. Shah AP, Bolch WE, Rajon DA, et al. A paired-image radiation transport model for skeletal dosimetry. J Nucl Med. 2005;46:344–353
  21. Siegel J, Thomas S, Stubbs J, et al. MIRD Pamphlet No 16—Techniques for Quantitative Radiopharmaceutical Biodistribution Data Acquisition and Analysis for Use in Human Radiation Dose Estimates. J Nucl Med. 1999;40:37S–61S
  22. Ogawa K, Harata Y, Ichihara T, et al. A practical method for position-dependent Compton-scatter correction in single emission CT. IEEE Trans Medimag. 1991;10:408–412
  23. King M, Farncombe T. An overview of attenuation and scatter correction of planar and SPECT data for dosimetry studies. Cancer Biother Radiopharm. 2003;18:181–190
  24. Autret D, Bitar A, Ferrer L, et al. Monte Carlo modeling of gamma cameras for I-131 imaging in targeted radiotherapy. Cancer Biother Radiopharm. 2005;20:77–84
  25. Dewaraja YK, Wilderman SJ, Ljungberg M, et al. Accurate dosimetry in I-131 radionuclide therapy using patient- specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005;46:840–849
  26. Kirschner A, Ice R, Beierwaltes W. Radiation dosimetry of 131I-19-iodocholesterol: The pitfalls of using tissue concentration data, the author's reply. J Nucl Med. 1975;16:248–249
  27. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–1372
  28. International Commission on Radiological Protection. ICRP Publication 53: Radiation Dose to Patients from Radiopharmaceuticals, 53. New York: Pergamon; 1989;
  29. International Commission on Radiological Protection. Radiation Dose to Patients from Radiopharmaceuticals (ICRP Publication 80). New York: Pergamon; 2000;
  30. Snyder W. Estimates of absorbed fraction of energy from photon sources in body organs (Medical Radionuclides: Radiation Dose and Effects). USAEC; 1970;33-50
  31. Hindorf C, Linden O, Stenberg L, et al. Change in tumor absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients. Clin Cancer Res. 2003;9:4003s–4006s
  32. Siegel JA, Stabin MG. Mass-scaling of S Values for blood-based estimation of red marrow absorbed dose: The quest for an appropriate method. J Nucl Med. 2007;48:253–256
  33. Traino AC, Di Martino FA. Dosimetric algorithm for patient-specific 131I therapy of thyroid cancer based on a prescribed target-mass reduction. Phys Med Biol. 2006;51:6449–6456
  34. Hartman Siantar CL. Impact of nodal regression on radiation dose for lymphoma patients after radioimmunotherapy. J Nucl Med. 2003;44:1322–1329
  35. Traino AC, Ferrari M, Cremonesi M, et al. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52:5231–5248
  36. Stabin MG, Stubbs JB, Toohey RE: Radiation Dose Estimates for Radiopharmaceuticals. NUREG/CR-6345, prepared for: US Nuclear Regulatory Commission, US Department of Energy, US Department of Health & Human Services, 81 pages, 1996
  37. International Commission on Radiological Protection. Radiation Dose Estimates for Radiopharmaceuticals (ICRP Publications 53 and 80, with addenda). New York: Pergamon Press; 1983;1991
  38. Kolbert KS, Sgouros G, Scott AM, et al. Implementation and evaluation of patient-specific three-dimensional internal dosimetry. J Nucl Med. 1997;38:301–308
  39. Dewaraja YK, Wilderman SJ, Ljungberg M, et al. Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation. J Nucl Med. 2005;46:840–849
  40. Liu A, Williams L, Lopatin G, et al. A radionuclide therapy treatment planning and dose estimation system. J Nucl Med. 1999;40:1151–1153
  41. Guy MJ, Flux GD, Papavasileiou P, et al. RMDP: A dedicated package for I-131 SPECT quantification, registration and patient-specific dosimetry. Cancer Biother Radiopharm. 2003;18:61–69
  42. Clairand I, Ricard M, Gouriou J, et al. DOSE3D: EGS4 Monte Carlo code-based software for internal radionuclide dosimetry. J Nucl Med. 1999;40:1517–1523
  43. Bielajew A, Rogers D. PRESTA: The parameter reduced electron-step transport algorithm for electron monte carlo transport. Nucl Instrum Methods. 1987;B18:165–181
  44. Briesmeister JF (ed): “MCNP—A General Monte Carlo N-Particle Transport Code, Version 4C,” LA-13709-M, Los Alamos National Laboratory April 2000
  45. Allison J, Amako K, Apostolakis J, et al. Geant4 developments and applications. IEEE Trans Nucl Sci. 2006;53:270–278
  46. Lehmann J, Hartmann Siantar C, et al. Monte Carlo treatment planning for molecular targeted radiotherapy within the MINERVA system. Phys Med Biol. 2005;50:947–958
  47. Sgouros G, Kolbert KS, Sheikh A, et al. Larson patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–1372
  48. DeNardo DA, DeNardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997;80:2558–2566
  49. Siegel JA, Lee RE, Pawlyk DA, et al. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Instrum (B). 1989;16:553–559
  50. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunoconj Radiopharmacol. 1990;3:213–233
  51. Lim S-M, DeNardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997;38:1474-1378
  52. Breitz H, Fisher D, Wessels B. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monocolonal antibody. J Nucl Med. 1998;39:1746–1751
  53. Eary JF, Krohn KA, Press OWQ, et al. Importance of pre-treatment radiation absorbed dose estimation for radioimmunotherapy of non Hodgkin's lymphoma. Nucl Med Biol. 1997;24:635–638
  54. Behr TM, Sharkey RM, Juweid ME, et al. Hematological toxicity in the radioimmunotherapy of solid cancers with 131I-labeled anti-CEA NP-4 IgG1. Dependence on red marrow dosimetry and pretreatment.in sixth international radiopharmaceutical dosimetry symposium. Jan 1999;Vol I:113–125Proceedings of May 7-10, 1996 Gatlinburg, TN, Symposium, ORAU
  55. Juweid ME, Zhang C-H, Blumenthal RD, et al. Prediction of hematologic toxicity after radioimmunotherapy with 131I-labeled anticarcinoembryoinic antigen monoclonal antibodies. J Nuc Med. 1999;10:1609–1616
  56. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation Dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: Combined data from 4 clinical trials. J Nucl Med. 2003;44:465–474
  57. Shen S, Meredith RF, Duan J, et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy. J Nucl Med. 2002;43:1245–1253
  58. Siegel JA, Yeldell D, Goldenberg DM, et al. Red marrow radiation dose adjustment using plasma FLT3-l cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med. 2003;44:67–76
  59. Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46:92S–98S(suppl)
  60. Kobe C, Eschner W, Sudbrock F, et al. Graves' disease and radioiodine therapy: Is success of ablation dependent on the achieved dose above 200 Gy?. Nuklearmedizin. 2008;47:13–17
  61. Smith RN, Wilson GM. Clinical trial of different doses of 131I in treatment of thyrotoxicosis. Br Med J. 1967;1:129–132
  62. Becker DV, McConahey WM, Dobyns BM, et al. The results of radioiodine treatment of hyperthyroidism. In:  Fellinger K,  Höfer R editor. Further Advances in Thyroid Research. Vienna, Austria: Verlage der wiener Medizinischen Akademie; 1971;p. 603–609
  63. Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm. 2005;20:47–51
  64. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm. 2003;18:89–97
  65. Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose–effect relationship. J Nucl Med. 2005;46:99S–106S
  66. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol. 1985;58:515
  67. Sachs RK, Hahnfeld P, Brenner DJ. The link between low-LET dose-response relations and the underlying kinetics of damage production/repair/misrepair. Int J Radiat Biol. 1997;72:351–374
  68. Lea DE, Catcheside DG. The mechanism of the induction by radiation of chromosome abberations in Tradescantia. J Genet. 1942;44:216–245
  69. Barendson GW. Dose fractionation, dose-rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982;8:1981–1987
  70. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679–694
  71. Malaroda A, Flux GD, Buffa FM, et al. Multicellular dosimetry in voxel geometry for targeted radionuclide therapy. Cancer Biother Radiopharm. 2003;18:451–461
  72. O'Donoghue JA, Sgouros G, Divgi CR, et al. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry. J Nucl Med. 2000;41:538–547
  73. Prideaux AR, Song H, Hobbs RF, et al. Three-dimensional radiobiologic dosimetry: Application of radiobiologic modeling to patient-specific 3-dimensional imaging–based internal dosimetry. J Nucl Med. 2007;48:1008–1016
  74. Bodey RK, Evans PM, Flux GD. Application of the linear-quadratic model to combined modality radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:228–241
  75. Hall EJ. The bystander effect. Health Phys. 2003;85:31–35
  76. Khan MA, Hill RP, Van Dyk J. Partial volume rat lung irradiation: An evaluation of early DNA damage. Int J Radiat Oncol Biol Phys. 1998;40:467/76
  77. Sgouros G, Knox SJ, Joiner MC, et al. MIRD continuing education: Bystander and low–dose-rate effects: Are these relevant to radionuclide therapy?. J Nucl Med. 2007;48:1683–1691
  78. Wessels BW, Bolch WE, Bouchet LG, et al. American Association of Physicists in Medicine Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison. J Nucl Med. 2004;45:1725–1733
  79. Eschmann SM, Reischl G, Bilger K, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29:760–767
  80. Canzi C, Zito F, Voltini F, et al. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. Med Phys. 2006;33:2860–2867
  81. Carlier T, Salaun PY, Cavarec MB, et al. Optimized radioiodine therapy for Graves' disease: Two MIRD-based models for the computation of patient-specific therapeutic I-131 activity. Nucl Med Commun. 2006;27:559–566
  82. Smith RN. Clinical trial of different doses of 131I in the treatment of thyrotoxicosis. Br Med J. 1967;1:129–131
  83. Grosso M, Traino A, Boni G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism. Cancer Biother Radiopharm. 2005;20:218–223
  84. Furhang EE, Larson SM, Buranapong P, et al. Thyroid cancer dosimetry using clearance fitting. J Nucl Med. 1999;40:131–136
  85. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid. 1997;7:183–187
  86. Reiners C. Radioiodine therapy of thyroid cancer. Tumordiagnostik Therapie. 1998;19:70–73
  87. Benua S, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–182
  88. Ott RJ, Tait D, Flower MA, et al. Treatment Planning for I-131 metaiodobenzylguanidine radiotherapy of neural crest tumors using I-124 metaiodobenzylguanidine positron emission tomography. Br J Radiol. 1992;65:787–791
  89. Sgouros G, Kolbert KS, Sheikh A, et al. Patient-specific dosimetry for I-131 thyroid cancer therapy using I-124 PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45:1366–1372
  90. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: Largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451–456
  91. Hanscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47:648–654
  92. Lassman M, Luste M, Hanschei H, et al. Impact of I-131 diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45:619–625
  93. Sisson JC, Avram AM, Lawson SA, et al. The so-called stunning of thyroid tissue. J Nucl Med. 2006;47:1406–1412
  94. Woolfenden JM. Thyroid stunning revisited. J Nucl Med. 2006;47:1403–1405
  95. Oyen WJG, Bodei L, Giammarile F, et al. Targeted therapy in nuclear medicine—current status and future prospects. Ann Oncol. 2007;18:1782–1792
  96. Ron E, Doody MM, Becker DV, et al. Cooperative Thyrotoxicosis Therapy Follow-up Study Group Cancer mortality following treatment for adult hyperthyroidism. JAMA. 1998;280:347–355
  97. Hoefnagel CA. Nuclear medicine therapy of neuroblastoma. Q J Nucl Med. 1999;43:336–343
  98. Matthay KK, Panina C, Huberty J, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with I-131-MIBG. J Nucl Med. 2001;42:1713–1721
  99. Gaze MN, Chang YC, Flux GD, et al. Feasibility of dosimetry-based high-dose I-131-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma. Cancer Biotherapy Radiopharm. 2005;20:195–199
  100. Monsieurs M, Brans B, Bacher K, et al. Patient dosimetry for I-131-MIBG therapy for neuroendocrine tumours based on I-123-MIBG scans. Eur J Nucl Med Mol Imaging. 2002;29:1581–1587
  101. Flux GD, Guy MJ, Papavasileiou P, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm. 2003;18:81–87
  102. Garber K. Users fear that lymphoma drugs will disappear. J Natl Cancer Inst. 2007;99:498–501
  103. Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin (TM) radioimmunotherapy for low-grade, follicular, or transformed B- cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol. 2001;39:181–194
  104. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: Principles and a simplified method for clinical implementation. J Nucl Med. 1998;39:14S–20S
  105. Cremonesi M, Ferrari M, Chinol M, et al. Dosimetry in radionuclide therapies with Y-90-conjugates: the IEO experience. Q J Nucl Med. 2000;44:325–332
  106. Hindorf C, Chittenden S, Causer L, et al. Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer Biother Radiopharm. 2007;22:130–135
  107. Barone R, Walrand S, Valkema R, et al. Correlation between acute red marrow (RM) toxicity and RM exposure during Y-90-SMT487 therapy. J Nucl Med. 2002;43:1267
  108. Esser JP, Krenning EP, Teunissen JJM, et al. TI Comparison of [Lu-177-DOTA(0), Tyr(3)] octreotate and [Lu-177- DOTA(0), Tyr(3)] octreotide: Which peptide is preferable for PRRT?. Eur J Nucl Med Mol Imaging. 2006;33:1346–1351
  109. Gotthardt M, van Eerd-Vismale J, Oyen WJG, et al. Indication for different mechanisms of kidney uptake of radiolabeled peptides. J Nucl Med. 2007;48:596–601
  110. EURATOM: Health protection of individuals against the dangers of ionising radiation in relation to medical exposure: Council directive 97/43 EURATOM, 1997
  111. Parthasarathy KL, Crawford ES. Treatment of thyroid carcinoma: Emphasis on high-dose 131I outpatient therapy. J Nucl Med Technol. 2002;30:165–171
  112. Solans R, Bosch J-A, Galofré P, et al. Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med. 2001;42:738–743
  113. Siegel JA, Stabin MG, Brill AB. The importance of patient-specific radiation dose calculations for the administration of radionuclides in therapy. Cell Mol Biol. 2002;48:451–459
  114. Thierens HM, Monsieurs MA, Bacher K. Patient dosimetry in radionuclide therapy: The whys and the wherefores. Nucl Med Commun. 2005;26:593–699(review)
  115. Robbins RJ, Schlumberger MJ. The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med. 2005;46:28S–37S

PII: S0001-2998(08)00073-1

doi: 10.1053/j.semnuclmed.2008.05.005

Seminars in Nuclear Medicine
Volume 38, Issue 5 , Pages 308-320 , September 2008

Article Tools

* Image Usage & Resolution